Giving four weeks of a targeted drug before starting chemotherapy improved response rates in a small group of patients with advanced pancreatic cancer, University of Michigan researchers report…"I think this trial here is a step back in the right direction of finding out what exactly is going on. I will say that when I read the abstract that the response rate was very high. Meaning that usually you'd see about a 5 or 9 percent chance of having a response to gemcitabine by itself, and here in this situation I think at least 23 percent, 25 percent," said conference chairman Dr. Daniel Von Hoff, physician-in-chief and distinguished professor at the Translational Genomic Research Institute and professor of medicine at the Mayo Clinic in Rochester, Minn.
HealthDay by Amanda Gardner
Tags: Cancer, Chemotherapy, Dr. Daniel Von Hoff, gemcitabine, Genomics, HealthDay, Mayo Clinic Rochester, pancreatic cancer, Research, Translational Genomics Research Institute, University of Michigan